Rapport Therapeutics (NASDAQ:RAPP) Trading 5.3% Higher – What’s Next?

Rapport Therapeutics (NASDAQ:RAPP)’s share price was up 5.3% on Monday . The stock traded as high as $23.40 and last traded at $23.21. Approximately 24,095 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 176,595 shares. The stock had previously closed at $22.05.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Jefferies Financial Group initiated coverage on Rapport Therapeutics in a research report on Tuesday, July 2nd. They issued a “buy” rating and a $35.00 price target on the stock. TD Cowen assumed coverage on shares of Rapport Therapeutics in a research report on Tuesday, July 2nd. They issued a “buy” rating on the stock. Finally, Stifel Nicolaus began coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 2nd. They set a “buy” rating and a $35.00 target price for the company.

Rapport Therapeutics Trading Up 0.0 %

The firm has a 50-day moving average of $20.52.

Rapport Therapeutics (NASDAQ:RAPP) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($1.02). As a group, equities analysts anticipate that Rapport Therapeutics will post -3.46 earnings per share for the current year.

Hedge Funds Weigh In On Rapport Therapeutics

Several hedge funds have recently made changes to their positions in the stock. TD Asset Management Inc bought a new position in Rapport Therapeutics in the 2nd quarter worth about $2,361,000. Johnson & Johnson bought a new position in shares of Rapport Therapeutics in the second quarter valued at approximately $58,105,000. Sofinnova Investments Inc. purchased a new position in Rapport Therapeutics during the second quarter valued at approximately $45,393,000. Davidson Kempner Capital Management LP purchased a new position in Rapport Therapeutics during the second quarter valued at approximately $229,000. Finally, ARCH Venture Management LLC bought a new stake in Rapport Therapeutics during the 2nd quarter worth approximately $86,730,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.